Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens

Eunüs S. Ali, Harinda Rajapaksha, Magnus Lundborg, Jillian M. Carr, Nikolai Petrovsky

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Human noroviruses are the leading causative agents of epidemic and sporadic viral gastroenteritis and childhood diarrhoea worldwide. Human histo-blood group antigens (HBGA) serve as receptors for norovirus capsid protein attachment and play a critical role in infection. This makes HBGA-norovirus binding a promising target for drug development. Recently solved crystal structures of norovirus bound to HBGA have provided a structural basis for identification of potential anti-norovirus drugs and subsequently performed in silico and in vitro drug screens have identified compounds that block norovirus binding and may thereby serve as structural templates for design of therapeutic norovirus inhibitors. This review explores norovirus therapeutic options based on the strategy of blocking norovirus-HBGA binding.

Original languageEnglish
Pages (from-to)14-22
Number of pages9
JournalAntiviral Research
StatePublished - Sep 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier B.V.


  • Antiviral therapy
  • Binding inhibitors
  • Human histo-blood group antigen
  • Norovirus
  • Norovirus capsid proteins

ASJC Scopus subject areas

  • Pharmacology
  • Virology


Dive into the research topics of 'Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens'. Together they form a unique fingerprint.

Cite this